首页 > 最新文献

In vivo最新文献

英文 中文
The Hemoglobin, Albumin, Lymphocyte and Platelet (HALP) Score as an Independent Prognostic Factor for Esophageal Cancer Patients who Received Curative Treatment.
IF 1.8 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-03-01 DOI: 10.21873/invivo.13892
Sosuke Yamamoto, Toru Aoyama, Yukio Maezawa, Itaru Hashimoto, Ryuki Esashi, Keisuke Kazama, Jyunya Morita, Shinnosuke Kawahara, Mamoru Uchiyama, Koji Numata, Kiyoko Shimada, Ayako Tamagawa, Aya Saito, Norio Yukawa

Background/aim: Esophageal cancer (EC) is a malignant tumor with poor prognosis. Prognostic factors that may be used in the treatment and management of EC are important. The purpose of this study was to evaluate the impact of the hemoglobin, albumin, lymphocyte, and platelet (HALP) score on the long-term oncological prognosis of patients with EC who have undergone curative treatment.

Patients and methods: Patients with EC who underwent curative resection at Yokohama City University between 2000 and 2020 were included. Clinical data were retrospectively retrieved from medical records and analyzed. The HALP score was determined as follows: HALP=[hemoglobin (g/l)×albumin (g/l)×lymphocytes (/l)]/platelets (/l). Kaplan-Meier method and Cox regression model were used to assess the overall (OS) and recurrence-free survival (RFS) and to evaluate the prognostic value of the HALP score.

Results: In total, 180 patients were included in this study. They were classified into the HALP-low (n=110) and HALP-high (n=70) groups using a cutoff value of 40. The 5-year OS rate was 46.9% in the HALP-low group and 66.0% in the HALP-high group (p=0.012). The 5-year RFS rate was 31.1% in the HALP-low group and 51.4% in the HALP-high group (p=0.006). The HALP score was found to be an independent prognostic factor for OS [odds ratio (OR)=1.954, 95% confidence interval (CI)=1.157-3.299, p=0.012] and RFS (OR=1.852, 95% CI=1.197-2.866, p=0.006).

Conclusion: The HALP score is a factor that predicts the oncological prognosis in patients with EC who have undergone radical resection.

{"title":"The Hemoglobin, Albumin, Lymphocyte and Platelet (HALP) Score as an Independent Prognostic Factor for Esophageal Cancer Patients who Received Curative Treatment.","authors":"Sosuke Yamamoto, Toru Aoyama, Yukio Maezawa, Itaru Hashimoto, Ryuki Esashi, Keisuke Kazama, Jyunya Morita, Shinnosuke Kawahara, Mamoru Uchiyama, Koji Numata, Kiyoko Shimada, Ayako Tamagawa, Aya Saito, Norio Yukawa","doi":"10.21873/invivo.13892","DOIUrl":"10.21873/invivo.13892","url":null,"abstract":"<p><strong>Background/aim: </strong>Esophageal cancer (EC) is a malignant tumor with poor prognosis. Prognostic factors that may be used in the treatment and management of EC are important. The purpose of this study was to evaluate the impact of the hemoglobin, albumin, lymphocyte, and platelet (HALP) score on the long-term oncological prognosis of patients with EC who have undergone curative treatment.</p><p><strong>Patients and methods: </strong>Patients with EC who underwent curative resection at Yokohama City University between 2000 and 2020 were included. Clinical data were retrospectively retrieved from medical records and analyzed. The HALP score was determined as follows: HALP=[hemoglobin (g/l)×albumin (g/l)×lymphocytes (/l)]/platelets (/l). Kaplan-Meier method and Cox regression model were used to assess the overall (OS) and recurrence-free survival (RFS) and to evaluate the prognostic value of the HALP score.</p><p><strong>Results: </strong>In total, 180 patients were included in this study. They were classified into the HALP-low (n=110) and HALP-high (n=70) groups using a cutoff value of 40. The 5-year OS rate was 46.9% in the HALP-low group and 66.0% in the HALP-high group (<i>p</i>=0.012). The 5-year RFS rate was 31.1% in the HALP-low group and 51.4% in the HALP-high group (<i>p</i>=0.006). The HALP score was found to be an independent prognostic factor for OS [odds ratio (OR)=1.954, 95% confidence interval (CI)=1.157-3.299, <i>p</i>=0.012] and RFS (OR=1.852, 95% CI=1.197-2.866, <i>p</i>=0.006).</p><p><strong>Conclusion: </strong>The HALP score is a factor that predicts the oncological prognosis in patients with EC who have undergone radical resection.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"885-893"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884460/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Alteration of Apparent Diffusion Coefficient Measurements Predict Survival Outcomes During Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.
IF 1.8 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-03-01 DOI: 10.21873/invivo.13897
Yuma Wada, Masaaki Nishi, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto, Mitsuo Shimada

Background/aim: Neoadjuvant chemoradiation therapy (nCRT) followed by surgery is recommended for patients with locally advanced rectal cancer (LARC). However, because 30%-40% of patients with LARC do not respond to nCRT, better prediction of treatment responses and survival outcomes is required. Therefore, this study aimed to identify apparent diffusion coefficient (ADC) values that predict survival outcomes after nCRT in patients with LARC.

Patients and methods: We analyzed data from 66 patients with LARC who underwent nCRT and evaluated the ADC values pre- and post-nCRT. Cox proportional hazard regression analyses were conducted to assess survival outcomes.

Results: There were no significant differences in disease-free survival (DFS) and overall survival (OS) between low and high ADC values pre-nCRT. However, patients classified as low ADC in post-nCRT had a significantly worse prognosis in OS and DFS (OS: p=0.01; DFS: p<0.01) than patients classified as high ADC. Moreover, an alteration in ADC values between pre- and post-nCRT was associated with poor OS [univariate, p<0.01; multivariate: p=0.01]. Finally, we identified ADC values that were significantly superior in predicting tumor regression grade, demonstrating remarkable diagnostic accuracy [post-nCRT: area under the curve (AUC)=0.79; alteration-nCRT: AUC=0.85].

Conclusion: We identified the clinical importance of changes in ADC values as a predictor of survival outcomes in patients with LARC. These results highlight the clinical importance of ADC values on improving the treatment strategies of patients.

{"title":"Alteration of Apparent Diffusion Coefficient Measurements Predict Survival Outcomes During Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.","authors":"Yuma Wada, Masaaki Nishi, Takuya Tokunaga, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto, Mitsuo Shimada","doi":"10.21873/invivo.13897","DOIUrl":"10.21873/invivo.13897","url":null,"abstract":"<p><strong>Background/aim: </strong>Neoadjuvant chemoradiation therapy (nCRT) followed by surgery is recommended for patients with locally advanced rectal cancer (LARC). However, because 30%-40% of patients with LARC do not respond to nCRT, better prediction of treatment responses and survival outcomes is required. Therefore, this study aimed to identify apparent diffusion coefficient (ADC) values that predict survival outcomes after nCRT in patients with LARC.</p><p><strong>Patients and methods: </strong>We analyzed data from 66 patients with LARC who underwent nCRT and evaluated the ADC values pre- and post-nCRT. Cox proportional hazard regression analyses were conducted to assess survival outcomes.</p><p><strong>Results: </strong>There were no significant differences in disease-free survival (DFS) and overall survival (OS) between low and high ADC values pre-nCRT. However, patients classified as low ADC in post-nCRT had a significantly worse prognosis in OS and DFS (OS: <i>p</i>=0.01; DFS: <i>p</i><0.01) than patients classified as high ADC. Moreover, an alteration in ADC values between pre- and post-nCRT was associated with poor OS [univariate, <i>p</i><0.01; multivariate: <i>p</i>=0.01]. Finally, we identified ADC values that were significantly superior in predicting tumor regression grade, demonstrating remarkable diagnostic accuracy [post-nCRT: area under the curve (AUC)=0.79; alteration-nCRT: AUC=0.85].</p><p><strong>Conclusion: </strong>We identified the clinical importance of changes in ADC values as a predictor of survival outcomes in patients with LARC. These results highlight the clinical importance of ADC values on improving the treatment strategies of patients.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"927-935"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884458/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Dosimetric Comparison of HyperArc Therapy Planning and Volumetric Modulated Arc Therapy Planning in Treating Patients With Glioblastoma Multiforme.
IF 1.8 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-03-01 DOI: 10.21873/invivo.13906
Wei-Ju Hong, Hsiu-Wen Ho, Hsiu-Man Lin, Tung Lin, Wan-Hsuan Chow, Ching-Chieh Yang, Li-Ching Lin

Background/aim: This study aimed at evaluating the potential benefit of automatic non-coplanar volumetric arc therapy (VMAT) (hyperarc, HA) technique in treating glioblastoma multiforme (GBM).

Patients and methods: Twenty-seven patients with GBM who received coplanar VMAT (C-VMAT) were selected in this study. HA and non-coplanar VMAT (NC-VMAT) plans were generated with the same prescriptions and constraints. The Target coverage, organs at risk (OARs) dose, and dosimetric indexes were compared among three plans.

Results: The HA plan demonstrated a reduction in dose to normal tissues while maintaining target coverage, compared to C-VMAT and NC-VMAT. Additionally, HA plans demonstrated higher coverage of the GTV and PTV60 as well as improved CI from PTV60 and PTV46 compared to the other plans. Regarding the dose gradient, HA plans showed a greater dose fall-off, resulting in reduced high-dose and intermediate-dose spillage at PTV46 The HA also demonstrated a tighter gradient radius at PTV60 and PTV46 The HA plan requires fewer MUs than both C-VMAT and NC-VMAT.

Conclusion: The HA plan had better dosimetric results compared to C-VMAT and NC-VMAT. The HA with automatic planning module and auto-delivery treatment also provided high-quality planning and delivery efficacy. These advantages suggest that HA could potentially escalate tumor doses while minimizing toxicity, thereby improving outcomes in GBM patients.

{"title":"A Dosimetric Comparison of HyperArc Therapy Planning and Volumetric Modulated Arc Therapy Planning in Treating Patients With Glioblastoma Multiforme.","authors":"Wei-Ju Hong, Hsiu-Wen Ho, Hsiu-Man Lin, Tung Lin, Wan-Hsuan Chow, Ching-Chieh Yang, Li-Ching Lin","doi":"10.21873/invivo.13906","DOIUrl":"10.21873/invivo.13906","url":null,"abstract":"<p><strong>Background/aim: </strong>This study aimed at evaluating the potential benefit of automatic non-coplanar volumetric arc therapy (VMAT) (hyperarc, HA) technique in treating glioblastoma multiforme (GBM).</p><p><strong>Patients and methods: </strong>Twenty-seven patients with GBM who received coplanar VMAT (C-VMAT) were selected in this study. HA and non-coplanar VMAT (NC-VMAT) plans were generated with the same prescriptions and constraints. The Target coverage, organs at risk (OARs) dose, and dosimetric indexes were compared among three plans.</p><p><strong>Results: </strong>The HA plan demonstrated a reduction in dose to normal tissues while maintaining target coverage, compared to C-VMAT and NC-VMAT. Additionally, HA plans demonstrated higher coverage of the GTV and PTV<sub>60</sub> as well as improved CI from PTV<sub>60</sub> and PTV<sub>46</sub> compared to the other plans. Regarding the dose gradient, HA plans showed a greater dose fall-off, resulting in reduced high-dose and intermediate-dose spillage at PTV<sub>46</sub> The HA also demonstrated a tighter gradient radius at PTV<sub>60</sub> and PTV<sub>46</sub> The HA plan requires fewer MUs than both C-VMAT and NC-VMAT.</p><p><strong>Conclusion: </strong>The HA plan had better dosimetric results compared to C-VMAT and NC-VMAT. The HA with automatic planning module and auto-delivery treatment also provided high-quality planning and delivery efficacy. These advantages suggest that HA could potentially escalate tumor doses while minimizing toxicity, thereby improving outcomes in GBM patients.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"1009-1021"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Case of EGFR-mutant Squamous Cell Lung Cancer Treated With Necitumumab Combination Therapy.
IF 1.8 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-03-01 DOI: 10.21873/invivo.13925
Minehiko Inomata, Daisuke Furukawa, Naoki Takata, Kotaro Tokui, Seisuke Okazawa, Shingo Imanishi, Satoshi Nomura

Background/aim: There is insufficient evidence regarding the optimal treatment for squamous cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations, and a standard treatment strategy has not been established.

Case report: A 60-year-old woman was diagnosed with advanced EGFR-mutant squamous cell lung cancer. She was treated with EGFR tyrosine kinase inhibitors and then received the combined therapy of cytotoxic agents plus immune checkpoint inhibitors as third-line therapy. She was then treated with the fourth-line combination therapy of cisplatin, gemcitabine, and necitumumab, which resulted in a progression-free survival of 5.0 months and shrinkage of the liver metastatic lesion.

Conclusion: The combination therapy of cisplatin, gemcitabine, and necitumumab was effective in treating pretreated EGFR-mutant squamous cell lung cancer in this case. It is necessary to accumulate more evidence to determine the most effective treatment for advanced EGFR-mutant squamous cell lung cancer.

背景/目的:关于表皮生长因子受体(EGFR)突变的鳞状细胞肺癌患者的最佳治疗方法,目前证据不足,标准治疗策略尚未确立:病例报告:一名 60 岁的女性被诊断出患有表皮生长因子受体突变的晚期鳞状细胞肺癌。她在接受表皮生长因子受体酪氨酸激酶抑制剂治疗后,又接受了细胞毒药物加免疫检查点抑制剂的三线联合治疗。随后,她又接受了顺铂、吉西他滨和奈替单抗的四线联合治疗,无进展生存期为5.0个月,肝转移病灶缩小:结论:顺铂、吉西他滨和新珠单抗联合疗法对该病例的表皮生长因子受体突变鳞状细胞肺癌治疗有效。晚期表皮生长因子受体突变鳞状细胞肺癌最有效的治疗方法还需积累更多证据。
{"title":"A Case of EGFR-mutant Squamous Cell Lung Cancer Treated With Necitumumab Combination Therapy.","authors":"Minehiko Inomata, Daisuke Furukawa, Naoki Takata, Kotaro Tokui, Seisuke Okazawa, Shingo Imanishi, Satoshi Nomura","doi":"10.21873/invivo.13925","DOIUrl":"10.21873/invivo.13925","url":null,"abstract":"<p><strong>Background/aim: </strong>There is insufficient evidence regarding the optimal treatment for squamous cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations, and a standard treatment strategy has not been established.</p><p><strong>Case report: </strong>A 60-year-old woman was diagnosed with advanced EGFR-mutant squamous cell lung cancer. She was treated with EGFR tyrosine kinase inhibitors and then received the combined therapy of cytotoxic agents plus immune checkpoint inhibitors as third-line therapy. She was then treated with the fourth-line combination therapy of cisplatin, gemcitabine, and necitumumab, which resulted in a progression-free survival of 5.0 months and shrinkage of the liver metastatic lesion.</p><p><strong>Conclusion: </strong>The combination therapy of cisplatin, gemcitabine, and necitumumab was effective in treating pretreated EGFR-mutant squamous cell lung cancer in this case. It is necessary to accumulate more evidence to determine the most effective treatment for advanced EGFR-mutant squamous cell lung cancer.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"1207-1210"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884446/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular Hydrogen Therapy for SLE-PAH: Case Report on Immune Marker Modulation.
IF 1.8 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-03-01 DOI: 10.21873/invivo.13926
Ting-Hao Tu, Jeng-Wei Lu, Chun-Hsien Wu, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Kuang-Yih Wang, Feng-Cheng Liu

Background/aim: Systemic lupus erythematosus-associated pulmonary arterial hypertension (SLE-PAH) is a severe complication marked by elevated pulmonary artery pressure, leading to exertional dyspnea and right-sided heart failure. Standard treatments frequently fall short in effectively controlling symptoms, highlighting the need for innovative therapeutic approaches. This aim of this study was to investigate the efficacy of molecular hydrogen therapy in a patient with SLE-PAH with decompensated right-side heart failure.

Case report: We present the case of a 51-year-old female diagnosed with SLE-PAH in 2012. Despite treatment with vasodilator agents, her condition worsened following an episode of sepsis, leading to severe dyspnea and oxygen desaturation since 2018. In March 2024, molecular hydrogen therapy was introduced as an adjuvant treatment. The patient received daily hydrogen capsules, which resulted in an increased percentage of Tr1 cells, and a decreased percentage of Treg cell subsets, B cell subsets, marginal cell, and plasma cell. Her clinical symptoms stabilized, and no adverse effects or complications were observed.

Conclusion: This case study highlights the potential efficacy of molecular hydrogen therapy in a patient with SLE-PAD and decompensated right-sided heart failure precipitated by sepsis. Further research is needed to confirm its therapeutic benefits, particularly its ability to modulate immune markers and improve clinical outcomes.

{"title":"Molecular Hydrogen Therapy for SLE-PAH: Case Report on Immune Marker Modulation.","authors":"Ting-Hao Tu, Jeng-Wei Lu, Chun-Hsien Wu, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Kuang-Yih Wang, Feng-Cheng Liu","doi":"10.21873/invivo.13926","DOIUrl":"10.21873/invivo.13926","url":null,"abstract":"<p><strong>Background/aim: </strong>Systemic lupus erythematosus-associated pulmonary arterial hypertension (SLE-PAH) is a severe complication marked by elevated pulmonary artery pressure, leading to exertional dyspnea and right-sided heart failure. Standard treatments frequently fall short in effectively controlling symptoms, highlighting the need for innovative therapeutic approaches. This aim of this study was to investigate the efficacy of molecular hydrogen therapy in a patient with SLE-PAH with decompensated right-side heart failure.</p><p><strong>Case report: </strong>We present the case of a 51-year-old female diagnosed with SLE-PAH in 2012. Despite treatment with vasodilator agents, her condition worsened following an episode of sepsis, leading to severe dyspnea and oxygen desaturation since 2018. In March 2024, molecular hydrogen therapy was introduced as an adjuvant treatment. The patient received daily hydrogen capsules, which resulted in an increased percentage of Tr1 cells, and a decreased percentage of Treg cell subsets, B cell subsets, marginal cell, and plasma cell. Her clinical symptoms stabilized, and no adverse effects or complications were observed.</p><p><strong>Conclusion: </strong>This case study highlights the potential efficacy of molecular hydrogen therapy in a patient with SLE-PAD and decompensated right-sided heart failure precipitated by sepsis. Further research is needed to confirm its therapeutic benefits, particularly its ability to modulate immune markers and improve clinical outcomes.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"1211-1219"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884449/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic Role of Prostate-specific Antigen Isoforms and Their Early Kinetics in Patients With Metastatic Castration-resistant Prostate Cancer Receiving New Generation Androgen Receptor Targeted Agents.
IF 1.8 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-03-01 DOI: 10.21873/invivo.13889
Ondřej Fiala, Petr Hošek, Hana Korunková, Michaela Tkadlecová, Milan Hora, Dominika Šiková, Petr Stránský, Jindřich Fínek, Radek Kučera, Jindra Windrichová, Ondřej Topolčan

Background/aim: New generation androgen receptor-targeting agents (ARTA) have been in the spotlight for their efficacy in metastatic castration-resistant prostate cancer (mCRPC). Prostate-specific antigen (PSA) represents one of the most commonly used serum cancer biomarkers worldwide. The present retrospective study focused on the prognostic role of serum PSA isoforms and their early dynamics in mCRPC patients treated with abiraterone acetate (ABI) or enzalutamide (ENZ).

Patients and methods: The association between outcomes of 334 mCRPC patients treated with ABI or ENZ and the levels of serum total PSA (tPSA), free PSA (fPSA), [-2]proPSA and the Prostate Health Index (PHI) at baseline and one month after treatment initiation was analyzed retrospectively.

Results: In the multivariable Cox proportional hazards models, baseline tPSA>50 μg/l (p<0.001), and [-2]proPSA>300 ng/l (p=0.017) remained independent significant factors associated with inferior OS, while baseline fPSA>1.75 μg/l (p=0.050) and Δ [-2]proPSA >-50% approached statistical significance (p=0.062). The results of ROC analyses assessing the ability of baseline tPSA, fPSA, and [-2]proPSA to predict mortality within two years showed area under the curve (AUC) values of 0.709, 0.685, and 0.740, respectively. Among the subgroup with baseline tPSA≤20.0 μg/l, the results of ROC analyses for baseline tPSA, fPSA and [-2]proPSA showed AUC values of 0.441, 0.682, and 0.688, respectively.

Conclusion: Our results suggest a significant correlation between pretreatment serum levels of tPSA and [-2]proPSA with OS in mCRPC patients receiving ARTA.

背景/目的:新一代雄激素受体靶向药物(ARTA)因其对转移性去势抵抗性前列腺癌(mCRPC)的疗效而备受关注。前列腺特异性抗原(PSA)是全球最常用的血清癌症生物标志物之一。本回顾性研究的重点是接受醋酸阿比特龙(ABI)或恩扎鲁胺(ENZ)治疗的mCRPC患者血清PSA同工酶的预后作用及其早期动态变化:回顾性分析了接受醋酸阿比特龙(ABI)或恩扎鲁胺(ENZ)治疗的334名mCRPC患者的预后与治疗开始后一个月的血清总PSA(tPSA)、游离PSA(fPSA)、[-2]proPSA和前列腺健康指数(PHI)水平之间的关系:在多变量考克斯比例危险模型中,基线tPSA>50微克/升(p300纳克/升(p=0.017))仍是与较差的OS相关的独立重要因素,而基线fPSA>1.75微克/升(p=0.050)和Δ [-2]proPSA>-50%接近统计学意义(p=0.062)。评估基线 tPSA、fPSA 和 [-2]proPSA 预测两年内死亡率能力的 ROC 分析结果显示,曲线下面积 (AUC) 值分别为 0.709、0.685 和 0.740。在基线 tPSA≤20.0 μg/l 的亚组中,基线 tPSA、fPSA 和 [-2]proPSA 的 ROC 分析结果显示 AUC 值分别为 0.441、0.682 和 0.688:我们的研究结果表明,接受ARTA治疗的mCRPC患者治疗前血清中tPSA和[-2]proPSA水平与OS之间存在明显的相关性。
{"title":"Prognostic Role of Prostate-specific Antigen Isoforms and Their Early Kinetics in Patients With Metastatic Castration-resistant Prostate Cancer Receiving New Generation Androgen Receptor Targeted Agents.","authors":"Ondřej Fiala, Petr Hošek, Hana Korunková, Michaela Tkadlecová, Milan Hora, Dominika Šiková, Petr Stránský, Jindřich Fínek, Radek Kučera, Jindra Windrichová, Ondřej Topolčan","doi":"10.21873/invivo.13889","DOIUrl":"10.21873/invivo.13889","url":null,"abstract":"<p><strong>Background/aim: </strong>New generation androgen receptor-targeting agents (ARTA) have been in the spotlight for their efficacy in metastatic castration-resistant prostate cancer (mCRPC). Prostate-specific antigen (PSA) represents one of the most commonly used serum cancer biomarkers worldwide. The present retrospective study focused on the prognostic role of serum PSA isoforms and their early dynamics in mCRPC patients treated with abiraterone acetate (ABI) or enzalutamide (ENZ).</p><p><strong>Patients and methods: </strong>The association between outcomes of 334 mCRPC patients treated with ABI or ENZ and the levels of serum total PSA (tPSA), free PSA (fPSA), [-2]proPSA and the Prostate Health Index (PHI) at baseline and one month after treatment initiation was analyzed retrospectively.</p><p><strong>Results: </strong>In the multivariable Cox proportional hazards models, baseline tPSA>50 μg/l (<i>p</i><0.001), and [-2]proPSA>300 ng/l (<i>p</i>=0.017) remained independent significant factors associated with inferior OS, while baseline fPSA>1.75 μg/l (<i>p</i>=0.050) and Δ [-2]proPSA >-50% approached statistical significance (<i>p</i>=0.062). The results of ROC analyses assessing the ability of baseline tPSA, fPSA, and [-2]proPSA to predict mortality within two years showed area under the curve (AUC) values of 0.709, 0.685, and 0.740, respectively. Among the subgroup with baseline tPSA≤20.0 μg/l, the results of ROC analyses for baseline tPSA, fPSA and [-2]proPSA showed AUC values of 0.441, 0.682, and 0.688, respectively.</p><p><strong>Conclusion: </strong>Our results suggest a significant correlation between pretreatment serum levels of tPSA and [-2]proPSA with OS in mCRPC patients receiving ARTA.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"859-869"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884487/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Renal Expression Levels of C5a Receptor and Autophagy-related Beclin-1 and LC3A/B Are Simultaneously Enhanced Under Immunoglobulin Treatment in a Rat Model of Sepsis.
IF 1.8 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-03-01 DOI: 10.21873/invivo.13883
Özlem Polat, Gunseli Orhun, Ilkay Anakli, Vuslat Yilmaz, Gizem Koral, Canan Ulusoy, Mert Canbaz, Perihan Ergin Ozcan, Erdem Tüzün, Figen Esen

Background/aim: Sepsis-induced acute kidney injury is a fatal, potentially reversible clinical condition. C5a receptor (C5aR) has been implied to play pivotal roles in both autophagy and sepsis-induced organ dysfunction. The aim of this study was to demonstrate the effects of intravenous immunoglobulin preparations on the expression of autophagy markers and investigate possible association between C5aR expression and autophagy in the kidney tissue of septic rats.

Materials and methods: Sepsis was induced by cecal ligation perforation (CLP) in rats, which were divided into control, sham, CLP+saline, CLP+IgG (250 mg/kg, iv), and CLP+immunoglobulins enriched with immunoglobulin M (IgGAM) (250 mg/kg, iv) groups. Kidney samples were obtained in two sets of experiments to examine the early (1 day) and late (10 days) effects of treatment. Renal expression levels of C5aR, LC3A/B, and beclin-1 were measured using immunoblotting.

Results: CLP did not enhance the renal expression of autophagy markers or C5aR. Contrariwise, IgG, and IgGAM administration reduced mortality caused by the CLP procedure and significantly increased C5aR, beclin-1, and LC3A/B expression levels in kidney samples of septic rats. Surviving rats had higher renal expression levels of C5aR, beclin-1, and LC3A/B than deceased rats. Expression levels of C5aR, beclin-1, and LC3A/B showed a strong correlation during the early stage of CLP-induced sepsis but not in the late stage.

Conclusion: Human-derived immunoglobulin preparations may ameliorate sepsis-related organ dysfunction partially through autophagy-related mechanisms. In the early stage of treatment, enhancement of autophagy in the kidney appears to be associated with C5aR expression.

{"title":"Renal Expression Levels of C5a Receptor and Autophagy-related Beclin-1 and LC3A/B Are Simultaneously Enhanced Under Immunoglobulin Treatment in a Rat Model of Sepsis.","authors":"Özlem Polat, Gunseli Orhun, Ilkay Anakli, Vuslat Yilmaz, Gizem Koral, Canan Ulusoy, Mert Canbaz, Perihan Ergin Ozcan, Erdem Tüzün, Figen Esen","doi":"10.21873/invivo.13883","DOIUrl":"10.21873/invivo.13883","url":null,"abstract":"<p><strong>Background/aim: </strong>Sepsis-induced acute kidney injury is a fatal, potentially reversible clinical condition. C5a receptor (C5aR) has been implied to play pivotal roles in both autophagy and sepsis-induced organ dysfunction. The aim of this study was to demonstrate the effects of intravenous immunoglobulin preparations on the expression of autophagy markers and investigate possible association between C5aR expression and autophagy in the kidney tissue of septic rats.</p><p><strong>Materials and methods: </strong>Sepsis was induced by cecal ligation perforation (CLP) in rats, which were divided into control, sham, CLP+saline, CLP+IgG (250 mg/kg, <i>iv</i>), and CLP+immunoglobulins enriched with immunoglobulin M (IgGAM) (250 mg/kg, <i>iv</i>) groups. Kidney samples were obtained in two sets of experiments to examine the early (1 day) and late (10 days) effects of treatment. Renal expression levels of C5aR, LC3A/B, and beclin-1 were measured using immunoblotting.</p><p><strong>Results: </strong>CLP did not enhance the renal expression of autophagy markers or C5aR. Contrariwise, IgG, and IgGAM administration reduced mortality caused by the CLP procedure and significantly increased C5aR, beclin-1, and LC3A/B expression levels in kidney samples of septic rats. Surviving rats had higher renal expression levels of C5aR, beclin-1, and LC3A/B than deceased rats. Expression levels of C5aR, beclin-1, and LC3A/B showed a strong correlation during the early stage of CLP-induced sepsis but not in the late stage.</p><p><strong>Conclusion: </strong>Human-derived immunoglobulin preparations may ameliorate sepsis-related organ dysfunction partially through autophagy-related mechanisms. In the early stage of treatment, enhancement of autophagy in the kidney appears to be associated with C5aR expression.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"810-818"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884498/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk Factors of Developing Leptomeningeal Seeding After Resection of Brain Metastasis in Patients With Breast Cancer: Defining the Indication for Preoperative SRS.
IF 1.8 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-03-01 DOI: 10.21873/invivo.13914
Ji Hyun Hong, Jieun Lee, Kabsoo Shin, Byung-Ock Choi, Jae Sung Park, Stephen Ahn, Jin-Ho Song

Background/aim: This study aimed to identify the incidence and risk factors for leptomeningeal seeding (LMS) in patients with breast cancer following brain metastasis resection and radiotherapy (RT) and to determine potential candidates for preoperative stereotactic radiosurgery (SRS).

Patients and methods: Between 2012 and 2022, 33 patients with breast cancer underwent surgical resection and postoperative RT for newly detected brain metastases. Twenty-one patients received whole-brain RT, while 12 patients were treated with SRS. Survival and incidence of LMS development were retrospectively analyzed. Several risk factors for the development of LMS were identified.

Results: After a median follow-up of 25.3 months, the 1- and 3-year overall survival (OS) rates were 81.2% and 58.1%, respectively. Development of LMS was the only significant factor affecting OS in multivariate analysis (Hazard ratio=3.08). Significant risk factors for LMS included age ≤45 years, triple-negative breast cancer (TNBC), and piecemeal resection. The 1-year LMS risk was 85.7% for younger patients, 46.2% for those with TNBC or piecemeal resection, and 11.1% for older patients without TNBC undergoing en-bloc resection.

Conclusion: Patients with breast cancer brain metastases who were ≤45 years old, had TNBC, or underwent piecemeal resection were at high risk of developing LMS, regardless of the postoperative RT technique used. Patients with these risk factors are essential candidates for alternative treatment approaches, such as preoperative SRS.

{"title":"Risk Factors of Developing Leptomeningeal Seeding After Resection of Brain Metastasis in Patients With Breast Cancer: Defining the Indication for Preoperative SRS.","authors":"Ji Hyun Hong, Jieun Lee, Kabsoo Shin, Byung-Ock Choi, Jae Sung Park, Stephen Ahn, Jin-Ho Song","doi":"10.21873/invivo.13914","DOIUrl":"10.21873/invivo.13914","url":null,"abstract":"<p><strong>Background/aim: </strong>This study aimed to identify the incidence and risk factors for leptomeningeal seeding (LMS) in patients with breast cancer following brain metastasis resection and radiotherapy (RT) and to determine potential candidates for preoperative stereotactic radiosurgery (SRS).</p><p><strong>Patients and methods: </strong>Between 2012 and 2022, 33 patients with breast cancer underwent surgical resection and postoperative RT for newly detected brain metastases. Twenty-one patients received whole-brain RT, while 12 patients were treated with SRS. Survival and incidence of LMS development were retrospectively analyzed. Several risk factors for the development of LMS were identified.</p><p><strong>Results: </strong>After a median follow-up of 25.3 months, the 1- and 3-year overall survival (OS) rates were 81.2% and 58.1%, respectively. Development of LMS was the only significant factor affecting OS in multivariate analysis (Hazard ratio=3.08). Significant risk factors for LMS included age ≤45 years, triple-negative breast cancer (TNBC), and piecemeal resection. The 1-year LMS risk was 85.7% for younger patients, 46.2% for those with TNBC or piecemeal resection, and 11.1% for older patients without TNBC undergoing en-bloc resection.</p><p><strong>Conclusion: </strong>Patients with breast cancer brain metastases who were ≤45 years old, had TNBC, or underwent piecemeal resection were at high risk of developing LMS, regardless of the postoperative RT technique used. Patients with these risk factors are essential candidates for alternative treatment approaches, such as preoperative SRS.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"1094-1103"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884462/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Standardized Pluchea Indica Leaf Extract Exhibited Antiproliferative Activity Against TGF-β-induced Prostate Stromal Cells (WPMY-1) Through G 1 Phase Cell Cycle Arrest via SMAD2/3 and ERK1/2 Signaling Pathways.
IF 1.8 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-03-01 DOI: 10.21873/invivo.13882
Yanisa Kanphet, Tamonwan Uttarawichien, Boonyadist Vongsak, Teerawat Boonsom, Nonthaneth Nalinratana, Sathiyaraj Sivaji, Pasarapa Towiwat, Suchada Sukrong

Background/aim: Benign prostatic hyperplasia (BPH) is characterized by the abnormal proliferation of prostate stromal cells, resulting in the enlargement of the prostate gland and the manifestation of troublesome symptoms, such as nocturia, urinary retention, and urinary incontinence. Dihydrotestosterone (DHT) and interleukin-17 (IL-17) are known to be key factors in promoting the overproduction of transforming growth factor-beta (TGF-β) in prostate stromal cells, contributing to their excessive proliferation, leading to BPH.

Materials and methods: In this study, selected plant extracts traditionally used to alleviate urinary symptoms were subjected to primary screening for their anti-proliferative activity by evaluating DHT- and IL-17-induced proliferation in WPMY-1 prostate stromal cells. This was followed by a secondary screening using TGF-β induction.

Results: The extract that significantly inhibited cell proliferation was standardized and further investigated for its anti-proliferative effects through the TGF-β signaling pathway. Results showed that the leaf extract of P. indica significantly inhibited cell proliferation induced by DHT, IL-17, and TGF-β. It was demonstrated that P. indica has anti-proliferative properties via the TGF-β signaling pathways by inhibiting PCNA protein expression and inducing cell accumulation at the G0/G1 phase, while reducing the cell population at the S phase. Additionally, it down-regulated the expression of both canonical (p-SMAD2/3) and non-canonical (p-ERK1/2) proteins in TGF-β-induced WPMY-1 cells.

Conclusion: The standardized leaf extract of P. indica showed notable anti-proliferative activity against TGF-β-induced WPMY-1 cells by arresting the cell cycle at the G0/G1 phase through the SMAD2/3 and ERK1/2 signaling pathways.

背景/目的:良性前列腺增生症(BPH)的特点是前列腺基质细胞异常增生,导致前列腺增大,并出现夜尿、尿潴留和尿失禁等令人烦恼的症状。众所周知,二氢睾酮(DHT)和白细胞介素-17(IL-17)是促进前列腺基质细胞过度产生转化生长因子-β(TGF-β)的关键因素,促使其过度增殖,从而导致前列腺增生症:在本研究中,通过评估 DHT 和 IL-17 诱导的 WPMY-1 前列腺基质细胞增殖,对传统上用于缓解泌尿系统症状的精选植物提取物进行了抗增殖活性初筛。随后,利用 TGF-β 诱导进行了二次筛选:结果:对明显抑制细胞增殖的提取物进行了标准化,并进一步研究了其通过 TGF-β 信号通路的抗增殖作用。结果表明,籼稻叶提取物能明显抑制 DHT、IL-17 和 TGF-β 诱导的细胞增殖。结果表明,籼稻叶提取物可通过 TGF-β 信号通路抑制 PCNA 蛋白的表达,诱导细胞在 G0/G1 期聚集,同时减少 S 期的细胞数量,从而具有抗增殖特性。此外,它还能下调 TGF-β 诱导的 WPMY-1 细胞中规范蛋白(p-SMAD2/3)和非规范蛋白(p-ERK1/2)的表达:P.indica的标准化叶提取物通过SMAD2/3和ERK1/2信号通路使细胞周期停滞在G0/G1期,从而对TGF-β诱导的WPMY-1细胞表现出显著的抗增殖活性。
{"title":"Standardized <i>Pluchea Indica</i> Leaf Extract Exhibited Antiproliferative Activity Against TGF-β-induced Prostate Stromal Cells (WPMY-1) Through G 1 Phase Cell Cycle Arrest <i>via</i> SMAD2/3 and ERK1/2 Signaling Pathways.","authors":"Yanisa Kanphet, Tamonwan Uttarawichien, Boonyadist Vongsak, Teerawat Boonsom, Nonthaneth Nalinratana, Sathiyaraj Sivaji, Pasarapa Towiwat, Suchada Sukrong","doi":"10.21873/invivo.13882","DOIUrl":"10.21873/invivo.13882","url":null,"abstract":"<p><strong>Background/aim: </strong>Benign prostatic hyperplasia (BPH) is characterized by the abnormal proliferation of prostate stromal cells, resulting in the enlargement of the prostate gland and the manifestation of troublesome symptoms, such as nocturia, urinary retention, and urinary incontinence. Dihydrotestosterone (DHT) and interleukin-17 (IL-17) are known to be key factors in promoting the overproduction of transforming growth factor-beta (TGF-β) in prostate stromal cells, contributing to their excessive proliferation, leading to BPH.</p><p><strong>Materials and methods: </strong>In this study, selected plant extracts traditionally used to alleviate urinary symptoms were subjected to primary screening for their anti-proliferative activity by evaluating DHT- and IL-17-induced proliferation in WPMY-1 prostate stromal cells. This was followed by a secondary screening using TGF-β induction.</p><p><strong>Results: </strong>The extract that significantly inhibited cell proliferation was standardized and further investigated for its anti-proliferative effects through the TGF-β signaling pathway. Results showed that the leaf extract of <i>P. indica</i> significantly inhibited cell proliferation induced by DHT, IL-17, and TGF-β. It was demonstrated that <i>P. indica</i> has anti-proliferative properties <i>via</i> the TGF-β signaling pathways by inhibiting PCNA protein expression and inducing cell accumulation at the G<sub>0</sub>/G<sub>1</sub> phase, while reducing the cell population at the S phase. Additionally, it down-regulated the expression of both canonical (p-SMAD2/3) and non-canonical (p-ERK1/2) proteins in TGF-β-induced WPMY-1 cells.</p><p><strong>Conclusion: </strong>The standardized leaf extract of <i>P. indica</i> showed notable anti-proliferative activity against TGF-β-induced WPMY-1 cells by arresting the cell cycle at the G<sub>0</sub>/G<sub>1</sub> phase through the SMAD2/3 and ERK1/2 signaling pathways.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"778-794"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utility of High-positioning Pelvic Pads in Laparoscopic Sigmoid Colon and Rectal Surgeries.
IF 1.8 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-03-01 DOI: 10.21873/invivo.13912
Masato Kitazawa, Satoshi Nakamura, Yuta Yamamoto, Satoru Miyazaki, Nao Hondo, Masahiro Kataoka, Hirokazu Tanaka, Yuji Soejima

Background/aim: The increased use of robotic rectal surgery has raised concerns regarding the increase in postoperative complications, e.g., compartment syndrome, associated with factors such as the Trendelenburg position, use of the adjustable lithotomy stirrup, and prolonged surgical duration. Therefore, in this study, we evaluated the utility of high-positioning pelvic pads during laparoscopic rectal and sigmoid colon surgeries, which is employed in our institution to maintain a stable body position with reduced head-down tilt.

Patients and methods: We included patients who underwent laparoscopic sigmoidectomy and rectal resection at Shinshu University Hospital between January 2016 and December 2021. We performed two studies: Study 1 compared the short-term treatment outcomes between patients who used high-positioning pelvic pads during surgery and those who did not, whereas Study 2 analyzed factors affecting the time to inferior mesenteric artery division using multivariate analysis.

Results: In Study 1, no significant differences in patient demographics were observed between the groups. The use of high-positioning pelvic pads significantly reduced the overall surgical time and number of gauzes used, with no significant differences in blood loss, complication rates, or duration of hospital stay. In Study 2, we identified intra-abdominal adhesions requiring adhesiolysis and use of high-positioning pelvic pads as factors influencing the time to inferior mesenteric artery division.

Conclusion: The use of high-positioning pelvic pads facilitated surgeries with a reduced head-down tilt, thereby contributing to shorter surgical times. This approach may help decrease the incidence of compartment syndrome, suggesting the need for further prospective trials and studies on robotic surgery.

{"title":"Utility of High-positioning Pelvic Pads in Laparoscopic Sigmoid Colon and Rectal Surgeries.","authors":"Masato Kitazawa, Satoshi Nakamura, Yuta Yamamoto, Satoru Miyazaki, Nao Hondo, Masahiro Kataoka, Hirokazu Tanaka, Yuji Soejima","doi":"10.21873/invivo.13912","DOIUrl":"10.21873/invivo.13912","url":null,"abstract":"<p><strong>Background/aim: </strong>The increased use of robotic rectal surgery has raised concerns regarding the increase in postoperative complications, <i>e.g.</i>, compartment syndrome, associated with factors such as the Trendelenburg position, use of the adjustable lithotomy stirrup, and prolonged surgical duration. Therefore, in this study, we evaluated the utility of high-positioning pelvic pads during laparoscopic rectal and sigmoid colon surgeries, which is employed in our institution to maintain a stable body position with reduced head-down tilt.</p><p><strong>Patients and methods: </strong>We included patients who underwent laparoscopic sigmoidectomy and rectal resection at Shinshu University Hospital between January 2016 and December 2021. We performed two studies: Study 1 compared the short-term treatment outcomes between patients who used high-positioning pelvic pads during surgery and those who did not, whereas Study 2 analyzed factors affecting the time to inferior mesenteric artery division using multivariate analysis.</p><p><strong>Results: </strong>In Study 1, no significant differences in patient demographics were observed between the groups. The use of high-positioning pelvic pads significantly reduced the overall surgical time and number of gauzes used, with no significant differences in blood loss, complication rates, or duration of hospital stay. In Study 2, we identified intra-abdominal adhesions requiring adhesiolysis and use of high-positioning pelvic pads as factors influencing the time to inferior mesenteric artery division.</p><p><strong>Conclusion: </strong>The use of high-positioning pelvic pads facilitated surgeries with a reduced head-down tilt, thereby contributing to shorter surgical times. This approach may help decrease the incidence of compartment syndrome, suggesting the need for further prospective trials and studies on robotic surgery.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"1078-1085"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
In vivo
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1